You are here: Industry Insights > Hummingbird

News List

Hummingbird Bioscience Announces UK MHRA Approval for First-in-Human Phase 1 Trial of HMBD-001 in Advanced Cancers prnasia
August 02, 2021
Hummingbird Bioscience today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the clinical trial application (CTA) to initiate first-in-human phase 1 trial of HMBD-001 in patients with advanced cancers.
Hummingbird Bioscience Appoints Renowned Scientist and Medical Oncologist Dr. Thomas J. Lynch to its Board of Directors prnasia
July 27, 2021
Hummingbird Bioscience announced that internationally renowned scientist and medical oncologist, Dr. Thomas J Lynch, Jr, MD, has been appointed to its Board as a Non-Executive Director, effective immediately.
Hummingbird Bioscience and MD Anderson Announce Strategic Research Collaboration To Advance Innovative Immunotherapies prnasia
July 12, 2021
Hummingbird Bioscience and The University of Texas MD Anderson Cancer Center today announced the launch of a multi-year strategic research collaboration to investigate and evaluate HMBD-002, Hummingbird's VISTA antagonist antibody.
Hummingbird Bioscience to Speak at 2021 Virtual Symposium: "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond" prnasia
June 15, 2021
Hummingbird today announced that its Chief Scientific Officer and co-founder, Dr Jerome Boyd-Kirkup, will be speaking at the 2021 virtual symposium "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond", taking place on June 18, 2021.
Hummingbird Bioscience and Novogene enter into strategic partnership to expand precision medicine testing for individuals with NRG1-fusion driven cancers in China prnasia
June 09, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced a strategic partnership with Asian genomic sequencing and bioinformatics company ...
Hummingbird Bioscience Announces Publication of Abstract on Anti-VISTA Antibody HMBD-002 at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting prnasia
May 31, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets today announced that its abstract reporting pre-clinical results from its V-domain immunoglobulin suppressor ...
Hummingbird Bioscience Raises US$125 Million in Series C Financing prnasia
May 19, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, announced the close of its US$125 million Series C financing round.
Hummingbird and Cancer Research UK to develop antibody drug HMBD-001 pharmaceutical-technology
August 09, 2019
Biotechnology company Hummingbird Bioscience and Cancer Research UK have collaborated to develop the former’s anti-HER3 clinical grade antibody drug, HMBD-001 to treat people with HER3 driven cancer.